Delving into the Latest Updates on Piramal Healthcare UK Ltd. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

SGLT2(钠-葡萄糖协同转运蛋白-2)	1

关联

1

项与 Piramal Healthcare UK Ltd. 相关的药物

Bexagliflozin

靶点

SGLT2

作用机制

SGLT2抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-01-20

2

项与 Piramal Healthcare UK Ltd. 相关的临床试验

CTR20212958 / Completed临床1期

评价THR-1442在中国健康受试者中安全性、耐受性、药代动力学特征的开放、单次和多次给药的I期临床研究

主要目的评价THR-1442在健康受试者中的安全性和耐受性；次要目的建立THR-1442健康受试者中的药代动力学特征；根据THR-1442在美国人群和日本人群的健康受试者药代动力学数据，进行间接比较在中国人群的药代动力学特征。

开始日期2021-11-30

申办/合作机构

恒翼生物医药（上海）股份有限公司

[+2]

CTR20210322 / Completed临床3期

一项在盐酸二甲双胍单药治疗后血糖控制不佳的2型糖尿病患者中接受盐酸二甲双胍联合Bexagliflozin（20 mg）片剂或达格列净（10 mg）片剂治疗的多中心、随机、双盲、平行、阳性对照的Ⅲ期临床研究

主要目的：在接受二甲双胍≥1500mg/天单药治疗，糖化血红蛋白（HbA1c）控制不佳的2型糖尿病（T2DM）患者中，评估Bexagliflozin或达格列净治疗24周后HbA1c较基线水平的降低，证明Bexagliflozin的疗效非劣于达格列净。次要目的：比较Bexagliflozin和达格列净治疗组之间，第24周较基线的体重变化比较Bexagliflozin与达格列净治疗组之间，第24周空腹血糖（FPG）较基线的变化比较Bexagliflozin和达格列净治疗组之间，第24周达到血糖疗效反应（定义为HbA1c<7.0%和<6.5%）的受试者比例比较Bexagliflozin和达格列净治疗组之间，第24周较基线的血压变化比较Bexagliflozin和达格列净治疗组之间，第24周餐后2h血糖（MTT试验2h点）相对基线的变化安全性目的：比较Bexagliflozin和达格列净治疗组之间对相关不良事件（AE）发生率的影响比较Bexagliflozin和达格列净治疗组之间对一般安全性评估的影响

开始日期2021-03-10

申办/合作机构

恒翼生物医药（上海）股份有限公司

[+2]

100 项与 Piramal Healthcare UK Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Piramal Healthcare UK Ltd. 相关的专利（医药）

登录后查看更多信息

5

项与 Piramal Healthcare UK Ltd. 相关的文献（医药）

2018-06-03·Drug Development and Industrial Pharmacy4区 · 医学

Design and evaluation of dental films of PEGylated rosin derivatives containing sparfloxacin for periodontitis

4区 · 医学

Article

作者: Barabde, Umesh V. ; Nande, Vishwanath S. ; Patil, Arun T. ; Joshi, Siddheshwar B. ; Morkhade, Dinesh M.

OBJECTIVEIn this study, PEGylated rosin derivatives (PRDs) namely D1 and D2 were synthesized and evaluated for their application to produce sustained-release antibacterial films containing sparfloxacin for periodontitis.SIGNIFICANCEPRDs are biodegradable and biocompatible, and therefore sustained-release dental implant of PRD-sparfloxacin can provide an effectual treatment for periodontitis.METHODSFilms were produced by solvent casting technique and characterized for morphology, swelling-index, in vitro degradation and drug release kinetics. The impact of type of PRD, concentration of PRDs, and addition of plasticizer (dibutyl phthalate) on various film properties was evaluated. The films were also subjected to stability study at 30 °C and 40 °C for 90 days.RESULTSBoth D1 and D2 produced smooth and non-porous films with sparfloxacin. The D1 films, due to lower amount of polyethylene glycol 400 in D1, exhibited lower swelling-index, slower degradation, and slower drug release compared to D2 films. An increase in PRDs concentration decreased swelling-index, prolonged degradation time, and decreased drug release rate of films; addition of plasticizer showed the similar effect. At pH 7.6, D1 and D2 films showed complete degradation at the end of 58 and 51 days, respectively. At the end of 21 days, D1 and D2 films released 41.85% and 61.53% sparfloxacin, respectively. The drug release from D1 films followed Higuchi square-root kinetics, while D2 films released drug by the zero order kinetics. The stability conditions did not significantly alter PRDs-film properties.CONCLUSIONResults revealed that PRDs can be used successfully to produce sustained-release antibacterial films containing sparfloxacin for the treatment of periodontitis.

2016-10-21·Organic Process Research & Development

Stereoselective Two-Step Biocatalysis in Organic Solvent: Toward All Stereoisomers of a 1,2-Diol at High Product Concentrations

作者: Rother, Dörte ; Jakoblinnert, Andre ; Wachtmeister, Jochen

Biotransformations on larger scale are mostly limited to cases in which alternative chem. routes lack sufficient chemo-, regio-, or stereoselectivity.Here, we expand the applicability of biocatalysis by combining cheap whole cell catalysts with a microaq. solvent system.Compared to aqueous systems, this permits manifoldly higher concentrations of hydrophobic substrates while maintaining stereoselectivity.We apply these methods to four different two-step reactions of carboligation and oxidoredn. to obtain 1-phenylpropane-1,2-diol (PPD), a versatile building block for pharmaceuticals, starting from inexpensive aldehyde substrates.By a modular combination of two carboligases and two alc. dehydrogenases, all four stereoisomers of PPD can be produced in a flexible way.After thorough optimization of each two-step reaction, the resulting processes enabled up to 63 g L^-1 product concentration (98% yield), space-time-yields up to 144 g L^-1 d^-1, and a target isomer content of at least 95%.Despite the use of whole cell catalysts, we did not observe any side product formation of note.In addition, we prove that, by using 1,5-pentandiol as a smart cosubstrate, a very advantageous cofactor regeneration system could be applied.

2015-08-01·International Journal of Pharmaceutics2区 · 医学

Formulation factors affecting acceptability of oral medicines in children

2区 · 医学

Article

作者: Thomas, Iwan W ; Flanagan, Talia ; Ranmal, Sejal ; Batchelor, Hannah K ; Orlu-Gul, Mine ; Tuleu, Catherine ; Kendall, Richard ; Ernest, Terry B ; Liu, Fang

Acceptability of medicines in children and caregivers affects safety and effectiveness of medicinal treatments. The pharmaceutical industry is required to demonstrate acceptability of new paediatric formulations in target age groups as an integrated part of the development of these products (Kozarewicz, 2014). Two questions arise when trying to tackle this task: "which dosage form to choose for each target age group?" and "how to formulate it once the dosage form is decided?". Inevitably, both the regulator and the developer turn to scientific evidence for answers. Research has emerged in recent years to demonstrate age-appropriateness and patient acceptability of different dosage forms; however, such information is still fragmented and far from satisfactory to define efficient formulation development strategies for a diverse patient subset (Ranmal and Tuleu, 2013). This paper highlights how formulation factors affect the acceptability of different oral medicines in children (Table 1), and it is based on a more extensive review article by Liu et al. (Liu et al., 2014). Gaps in knowledge are highlighted in order to stimulate further research. In some areas, findings from studies conducted in adult populations may provide useful guidance for paediatric development and this is also discussed.

100 项与 Piramal Healthcare UK Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Piramal Healthcare UK Ltd. 相关的转化医学

登录后查看更多信息